What is the suitable starting dose of Megace (megestrol acetate) for an elderly patient?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 3, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the FDA Drug Label

The recommended adult initial dosage of megestrol acetate oral suspension, USP is 800 mg/day (20 mL/day). The suitable starting dose of Megace (megestrol acetate) for an elderly patient is 800 mg/day.

  • This dose is based on the recommended adult initial dosage.
  • No specific dose adjustment is mentioned in the label for elderly patients, so the standard adult dose is applied. 1

From the Research

The recommended starting dose of Megace (megestrol acetate) for an elderly patient is 200 mg daily, which can be titrated upward as needed and tolerated, due to the potential for adverse effects such as adrenal suppression, thromboembolic events, and hyperglycemia, as reported in studies such as 2. When initiating Megace in elderly patients, it's crucial to monitor for potential side effects, which may include fluid retention, hyperglycemia, adrenal suppression, and increased risk of thromboembolic events.

  • Elderly patients often have altered pharmacokinetics and may be more sensitive to medications, so starting at a lower dose allows for assessment of tolerability.
  • The medication should be taken consistently, preferably with food, and patients should be evaluated regularly for effectiveness and adverse effects.
  • Megace works by stimulating appetite through multiple mechanisms, including antagonism of pro-inflammatory cytokines and direct effects on the hypothalamic feeding center, which explains its effectiveness in treating anorexia in the elderly population, as noted in studies like 2 and 3. Key considerations in the management of elderly patients on Megace include:
  • Regular monitoring of blood glucose levels due to the risk of hyperglycemia, as indicated in 4.
  • Assessment for signs of adrenal insufficiency, such as hypotension and fatigue, as reported in cases like those in 3 and 5.
  • Evaluation for thromboembolic events, given the increased risk associated with Megace therapy, as highlighted in 6.

References

Research

Megestrol acetate-associated adrenal insufficiency.

The American journal of geriatric pharmacotherapy, 2008

Research

Primary symptomatic adrenal insufficiency induced by megestrol acetate.

The Netherlands journal of medicine, 2013

Research

Megestrol acetate-induced adrenal insufficiency.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2008

Research

Megestrol acetate therapy in geriatric patients: case reviews and associated deep vein thrombosis.

The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists, 2003

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.